Akebia Therapeutics (AKBA) Misses Q2 EPS by 3c

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $56.4 million versus the consensus estimate of $59.1 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Creatd files Form S-1 and reports Q1 2026 financial results
• Goldman "broadly" raises estimates for LTL and truckload stocks